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ABSTRACT
Introduction
Kidney stones affect 1 in every 11 people in the United States each year. There is a
significant high recurrence rate without a stone prevention protocol. Alkali citrate is
beneficial in decreasing stone recurrence, but due to the cost and gastrointestinal side
effects there is a low adherence rate. This study aims to serve as a review of some of the
most commonly used alkalizing over‐ the‐ counter supplements that are advertised to
prevent and treat kidney stones.
Methods
Data was gathered by a comprehensive online literature search and company inquiries for
kidney stone prevention supplements. An additional informal poll of the authors selected
supplements that are most commonly taken by their patients. A total of eight supplements
were evaluated for cost, alkali equivalent provided, dosing and regulatory information.
Results
Eight of the most commonly used supplements were reviewed with a focus on alkalizing
agents. Information reviewed revealed dosing recommendations resulting in decreased
citrate alkali equivalents per day compared to prescription‐strength potassium citrate.
Cost, peer‐reviewed study results and regulatory data were reviewed, tabulated and
analyzed. Cost per alkali equivalent was substantially decreased for each supplement
compared to the prescribed drug. All supplements were found to be readily available
online.
Conclusion
Over‐ the‐ counter alkalizing agents are available to patients and may be an appropriate
alternative to cost prohibitive potassium citrate when treating urolithiasis patients.
Additional testing will be necessary in the future to determine the efficacy of these
supplements in the treatment and prevention of urinary stone disease.
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INTRODUCTION:
Kidney stones affect 1 in every 11 people in the United States each year.1 Unfortunately,
without dietary and/or medical management kidney stones can have a significant
recurrence rate, highlighting the importance of prevention.2 The American Urological
Association (AUA) guidelines recognize the effectiveness of medical management at
decreasing the recurrence of stone disease and recommend that clinicians offer
pharmacologic therapy to recurrent stone formers.3,4 Several clinical trials have
demonstrated the effectiveness of potassium citrate in decreasing stone recurrence.5,6
However, among kidney stone patients prescribed potassium citrate for stone
management, only 13% are adherent with the medication.7 Low adherence to stone
preventative therapy is likely multifactorial. Side effects associated include abdominal pain
and diarrhea.9
Another significant barrier to medication adherence is its cost. Potassium citrate retails at
an average cost of $154.80 for a one‐month supply of the generic formulation at a dosage
of 15 milli equivalents (mEq) twice daily (BID).10 This is notable considering that the urine
alkalinization is a long‐term therapy. Anecdotally, patients often report insurance
formularies do not cover commonly prescribed potassium citrate formulations. The
combination of the effectiveness of the medications with the prohibitory cost of the
prescription has led to the development of multiple over‐the‐counter supplements that
promise to alkalize the urine and/or decrease the risk of future kidney stones.
A simple Amazon search for “kidney stone medicine” returns more than 250 results.
Although the manufacturing of over‐the‐counter options is not regulated, and many are
not scientifically tested to the same degree as prescribed alkali citrate, they may be
effective and the affordability may increase patient compliance and adherence.
We review the more common over‐the‐counter supplements advertised to prevent or
directly treat kidney stones, specifically focusing on alkalizing agents. The intent of this
review is to educate providers on the supplements available to their patients, especially
patients who frequently self‐educate and self‐prescribe without direct oversight from the
treating physician. Shared decision making is a critical part of a patient‐provider
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essential in strengthening that relationship. While the goal of this review is not to promote
or advertise for any of the described supplements, a baseline knowledge of these options
may prove useful in the event patients inquire about them or self‐administer.
Urinary Alkalization
The common Western diet includes a large acid load, predominantly from animal protein
intake. In the kidneys, acid loads cause increased citrate uptake in renal cells leading to
lower urinary citrate and increased supersaturation of calcium salts. Urinary citrate is
thought to decrease stone recurrence by complexing with calcium in the urine, which
increases the solubility and reduces the concentration of free calcium in the urine, as well
as by binding the surface of crystals to prevent agglomeration and growth.8 In vitro, citrate
has been shown to inhibit calcium oxalate precipitation and decrease calcium phosphate
growth.11,12 Hence, alkali supplementation to raise urine pH and limit urine citrate uptake
is recommended for stone formers with low urine pH and/or urinary citrate.4
Multiple ingestible forms of alkali exist. Baseline knowledge of urinary alkalization is
important when reviewing over‐the‐counter alkali preparations. The most commonly
prescribed alkali for stone prevention is potassium citrate, which has demonstrated as high
as a 75% risk reduction of kidney stone recurrence, with a long‐term durable response in
some patients.13,14 Although similar, citric acid, a protonated form of citrate, is less
effective at increasing urinary citrate due to the counterproductive acid load.15
These differences have potential significance when dietary beverages are being used to
prevent stones. For example, lemonade therapy is commonly recommended to stone
formers as a way to increase urinary citrate. Orange juice, however, may in fact be more
effective given a greater portion of potassium citrate versus citric acid.16,17Coconut water,
due to a large malate as alkali component, can also increase urinary citrate if ingested in
large quantities.18 In addition, some citrus‐flavored carbonated beverages also contain
large portions of alkali due to citrate and malate content, however, substantial volumes of
these beverages would need to be ingested to match the alkali content of prescribed
potassium citrate.19
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bicarbonate demonstrating similar efficacy to potassium citrate at raising urine pH and
urine citrate.20,21
The cation associated with each alkali salt can have important consequences. Sodium
administration can increase blood pressure and decrease bone mineral retention. Most
importantly for kidney stone patients, it has a hypercalciuric effect that can be
counterproductive.20 Magnesium citrate also increases urine pH, but is associated with
significant gastrointestinal effects which can counterproductively increase urinary oxalate
through malabsorption.22 Additionally, magnesium can decrease intestinal absorption of
oxalate. Lastly, potassium lowers urine calcium and increases urine citrate20 but can be
dangerous for patients with renal failure or significant cardiac disease, and therefore
requires close monitoring.13
Regulation
The Food and Drug Administration (FDA) is the governing body regulating the content and
sale of domestically produced food and pharmaceuticals in the United States. For
approved pharmaceuticals, good manufacturing processes (GMPs) are regulated by the
FDA to ensure the identity, strength, quality, and purity of drug products is maintained.
Generally Recognized as Safe (GRAS) is a FDA designation that a chemical or substance is
considered safe by experts. Any substance added to a food is subject to review and
approval by the FDA, unless said substance is identified as GRAS.
Many over‐the‐counter treatments for kidney stone formers are marketed as medical
foods or supplements. Per the FDA and based on the United States Orphan Drug Act, a
medical food is “a food which is formulated to be consumed or administered enterally
under the supervision of a physician and which is intended for the specific dietary
management of a disease or condition for which distinctive nutritional requirements,
based on recognized scientific principles, are established by medical evaluation”.23 The
FDA does not approve supplements. The United States Pharmacopeia Convention is a non‐
profit organization that publishes an annual compendium of drug information, the United
States Pharmacopeia (USP). In order to assure quality among supplements and protect
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ingredients and products. A multi‐step evidence‐based process is used to confirm the
accuracy of the information supporting the quality of each product being verified in a
particular program. However, it is important to note that USP has no role in enforcement
of these standards. Hence, manufacturer claims must be carefully considered. In
particular, only supplements that have been tested and meet the USP program
requirements are allowed to display the USP Verified Dietary Supplement mark. This is not
equivalent to manufacturers who claim to adhere to USP standards without verification.
METHODS:
A comprehensive search for “kidney stone medications” and “kidney stone medicine” was
performed on online shopping websites that are likely visited by patients (i.e., Amazon,
Google). In addition, an informal poll of the authors was undertaken to determine the
supplements that are most commonly taken by their patients. Product information was
obtained from manufacturer websites and via company inquiries. Scientific literature
search was performed via PubMed, with manuscripts reviewed and summarized in the
results. Any additional available literature regarding the various products was reviewed
and reported.
RESULTS:
Eight supplements were reviewed, with a focus on alkalizing agents. See Table 1 for
summary of the alkali containing supplements. Commercial potassium citrate comes in
three doses: 5, 10, or 15 mEq of alkali. As seen in Table 1, most supplements provide a
fraction of this amount.
Pure Alkalizing Agents:
A search for “Potassium Citrate” on Amazon returned 213 products; we reviewed three of
these products. NOW® Potassium Citrate is “Amazon’s Choice,” BulkSupplements is the
most reviewed potassium citrate product with over 1400 reviews, and Litholyte® was
selected based on its popularity among patients.
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more commonly reviewed products are BulkSupplements (Hard Eight Nutrition LLC,
Henderson, NV, USA) and NOW® Potassium Citrate (NOW, Bloomingdale, IL, USA).24,25 Each
of these is available as a powder. The BulkSupplements formulation has 99 mg of
potassium citrate (0.92 mEq of alkali) per serving of 275 mg (3.33 mEq of alkali/1 gm
supplement) whereas the NOW® Potassium Citrate powder has 448 mg of potassium
citrate (4.15 mEq of alkali) per serving of 1.4 grams (2.96 mEq of alkali/1 gm supplement).
NOW® Potassium Citrate also comes in a 99 mg vegetarian capsule (0.92 mEq of alkali).
Again, for comparison commercial potassium citrate contains between 5‐15 mEq of alkali
per tablet. BulkSupplements is made in an FDA‐registered facility.
Litholyte® (Litholyte Corporation, New Bern, NC, USA) is a powdered mixture of potassium
citrate, magnesium citrate and sodium bicarbonate developed by urologist Ryan Holland,
MD.26 Each packet contains 10 mEq of alkali and the manufacturers recommend twice
daily dosing (see Table). It has zero calories and is unflavored to allow incorporation into a
liquid of the patient’s choice. The inventors note there is no citric acid in this product
leading to a net alkali effect on systemic pH. There are currently no peer‐reviewed
publications evaluating Litholyte®. However, the manufacturer cites studies that
demonstrate the benefit of sodium bicarbonate or combination potassium and magnesium
citrate versus placebo.25,26 This is not marketed as a prescription medication. It is still
patent pending but has been classified by the FDA as a medical food.
Combination Alkalizing and Vitamin Supplements:
There are several available alkalizing supplements that combine citrate with vitamin B6
and magnesium including TheraLithXR, StoneStopTM, KSPTabs, Kidney C.O.P. and
LithobalanceTM TheraLithXR (Theralogix LLC, Aston, PA, USA) is a supplement that
contains vitamin B6 (7.5 mg), magnesium (180 mg) and potassium citrate (99 mg/0.92
mEq), in a delayed‐release coating.27 The magnesium included is both magnesium citrate
(1.2 mEq) and magnesium oxide. The supplement is dye‐free, gluten‐free and is made in
the United States. The recommended dosage is two tablets twice a day with food. A study
in 2006 at Stony Brook University Hospital found normalization of urinary magnesium and
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urinary magnesium and citrate.28 TheraLithXR retails for $60.00 per bottle (90 day
supply).
StoneStop (StoneStop LLC Wilmington, DE, USA) is an over‐the‐counter pH‐neutral mixture
of citrate, magnesium, and vitamin B6 in individual packets.29 StoneStop was developed by
urologist Kyle Wood, MD. The dosage of each ingredient is not immediately available to
consumers. Each packet is mixed into 16 ounces of water and dissolved, and the
recommendation is to consume two packets daily. Like Litholyte, it is advertised as a
medical food and recommended to be used under medical supervision. Since the cation
complexed with citrate is magnesium, rather than sodium or potassium, the dosage may
be limited by gastrointestinal side effects, specifically, diarrhea. Retail price is 30 packets
for $29.99.
KSPtabs (Austin, TX, United States) are dissolving effervescent tablets developed by
urologist Michael Trotter, MD.30 Manufacturer recommendation is to consume one tablet
in 16 ounces of water, 2‐3 times per day. One KSPtab contains vitamin B6 (7.5 mg),
magnesium (64 mg), sodium bicarbonate (170 mg/ 2 mEq) and potassium bicarbonate
(100 mg/1mEq). The tablets come in two flavors, lime and berry, and are advertised as
gluten‐free, vegan friendly and all‐natural. They are sweetened with dextrose and stevia.
Each tablet is 10 calories and has 1 gram of sugar. The company has made available a self‐
produced study investigating urinary parameters in 35 nephrolithiasis patients who had
taken the supplement. The study found increased urinary outputs and urine pH, citrate
and magnesium with decreased urinary calcium and super saturation of uric acid on 24‐
hour urine analysis following administration of KSPtabs. This study is available on their
website.30 However, there are currently no peer‐reviewed studies reported using KSPtabs
to prevent kidney stones. Eighty tablets (approximately 1‐month supply) retail for $59.95.
Kidney C.O.P. (Calcium Oxalate Protector, Calcium Oxalate Labs Inc., Ft. Lauderdale, FL,
USA) is a patented formulation that combines five ingredients, each suggested to prevent
stone growth.31 In addition to citric acid (4.5 mEq), vitamin B6 and magnesium, Kidney
C.O.P. also includes Phytin and Musa Paradisiaca. Phytin (Inositol) is a known
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when combined with magnesium in vitro.32,33 Musa Paradisiaca (Banana Stem) has
traditionally been used as a natural remedy for stone prevention. Formal evidence
supporting this is sparse in the literature, but proposed mechanisms include a diuretic
effect as well as decreased activity of liver enzymes that are involved in oxalate
production. One small series suggested efficacy when used among a rat model of ethylene
glycol induced nephrolithiasis.34 The Kidney C.O.P. website claims that in vitro testing of
the patented formula led to a 99% inhibition of calcium oxalate growth rate; these findings
could not be verified by peer‐reviewed literature at the time of publication. Furthermore,
the website’s disclaimer notes that the proposed stone prevention mechanism has not
been evaluated by the FDA.
LithoBalanceTM (AmPurity NutraceuticalsTM, Fenton, MO, USA) is a combination of vitamin
B6, magnesium citrate and potassium citrate sweetened with stevia leaf extract.35 The
recommended serving size is one scoop (10 grams), dissolved in 12‐16 ounces of water, 2
to 3 times daily with meals. One scoop contains 20 mg vitamin B6, 43 mg (0.6 mEq)
magnesium citrate, 410 mg (3.8 mEq) potassium citrate and 150 mg Stevia leaf extract. No
artificial colors, sweeteners or flavors are claimed to be added. The product is claimed to
have been developed by a team of clinical urologists and research scientists. The website
refers to several publications related to the effect on stone formation of potassium citrate,
magnesium citrate, vitamin B6, and magnesium oxide (dihydrate). In the referenced
studies, there are several combinations and dosages of these ingredients mentioned,
however there is no published literature on the specific combination and quantities of the
materials in LithoBalanceTM in the literature, and no publications on LithoBalanceTM
specifically. One container contains 90 servings (approximately 1‐month supply) and retails
for $49.89.
Chanca Piedra‐ containing Supplements:
A simple online search for “kidney stone medicine” will lead patients to dozens of products
with Phyllanthus niruri (Chanca Piedra). Phyllanthus niruri (Chanca Piedra, Spanish for
“stone breaker”) is a plant used in both Ayurvedic systems of medicine in India and in folk
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indicating that Chanca Piedra has a role in decreasing kidney stones, increasing urine
potassium, and decreasing urinary oxalate and urinary uric acid.37‐39 However, the need for
additional rigorously performed studies persists. Given that the scope of this paper is to
focus on alkalinizing agents, products containing Phyllanthus niruri were not reviewed in
great detail here.
DISCUSSION:
The high prevalence of kidney stone disease makes access to medical therapies a necessity
for patients. Unfortunately, the high cost and side effects of prescription potassium citrate
is prohibitive for many patients and results in low adherence.7 A 2013 survey found that
72% of patients look online for health information.40 Patients are likely using similar search
engines to find accessible and affordable alternatives to expensive prescription
medications. Providers need to be aware of these formulations to appropriately counsel
patients on the risks and benefits of such therapies.
It must be emphasized that none of these products are FDA approved for the treatment of
kidney stones and they have little to no scientific data to support the manufacturers’
claims. In fact, KSPtabs and TheraLithXR are the only supplements reviewed here that are
associated with any documented studies on the product.28,30 Litholyte® and StoneStop are
classified as medical foods. The medical food category became popular in the late 1980s
and 1990s and has grown into a lucrative business, valued at $12.3 billion in 2015 and
expected to surpass $24 billion by 2025.41 As mentioned above, a medical food is a product
designed to be consumed for the specific dietary management of a disease or condition.23
Medical foods are not regulated by the FDA but manufacturing of the products must
comply with the FDA regulations for food.23
This review briefly discusses a few of the more popular alternatives to prescription
potassium citrate. The alkalizing formulations available deserve further study. The non‐
alkalizing supplements were included so providers have basic knowledge of the products
marketed to urolithiasis patients. Providers should use this guide as a tool for an open
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for medication or supplement recommendations.
CONCLUSIONS:
Over‐ ‐the counter alkalizing agents are available to patients and may be an appropriate
alternative to cost prohibitive potassium citrate when treating urolithiasis patients.
Additional testing will be necessary in the future to determine the efficacy of these
supplements in the treatment and prevention of urinary stone disease.
ACKNOWLEDGEMENT
The authors are grateful to Dr. John Asplin for his insightful review of this manuscript.

Page 14 of 22

14

Journal of Endourology
Alkalinizing agents: a review of prescription, over‐the‐counter, and medical food supplements (DOI: 10.1089/end.2019.0292)
This paper has been peer‐reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Downloaded by Thomas Jefferson University from www.liebertpub.com at 08/22/19. For personal use only.

REFERENCES:
1. Scales CD Jr, Smith AC, Hanley JM, et al. Prevalence of kidney stones in the
United States. Eur Urol 2012;62(1):160‐5.
2. Uribarri J, Oh MS, Carroll HJ. The first kidney stone. Ann Intern Med
1989;111(12):1006‐9.
3. Pearle MS, Roehrborn CG, Pak CY, et al. Meta‐analysis of randomized trials for
medical prevention of calcium oxalate nephrolithiasis. J Endourol 1999;13:679‐
85.
4. Pearle MS, Goldfarb DS, Assimos DG, et al. American Urological Association.
Medical management of kidney stones: AUA guideline. J Urol. 2014; 192(2):316‐
24.

5. Ettinger B, Pak CY, Citron JT, et al. 1997. Potassium‐magnesium citrate is an
effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol
1997;158:2069‐73.
6. Barcelo P, Wuhl O, Servitge E, et al. Randomized double‐blind study of
potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol
1993;150:1761‐64.
7. Dauw CA, Yi Y, Bierlein MJ, et al. Factors associated with preventive
pharmacological therapy adherence among patients with kidney stones.
Urology 2016;93:45‐9.
8. Zuckerman JM, Assimos DG. 2009. Hypocitrauria: pathophysiology and medical
management. Reviews in Urology 2009;11(3):134‐44.
9. Morgan MSC, Pearle MS. Medical management of renal stones. BMJ
2016;352:i52.
10. https://www.goodrx.com/potassiumcitrate?dosage=15meq&form=tablet&label
_override=potassium+citrate&quantity=60. Accessed December 10, 2018.

Page 15 of 22

15
11. Nicar MJ, Hill K, Pak CY. Inhibition by citrate of spontaneous precipitation of
Journal of Endourology
Alkalinizing agents: a review of prescription, over‐the‐counter, and medical food supplements (DOI: 10.1089/end.2019.0292)
This paper has been peer‐reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Downloaded by Thomas Jefferson University from www.liebertpub.com at 08/22/19. For personal use only.

calcium oxalate in vitro. J Bone Miner Res 1987; 2:215–20.
12. Meyer JL, Smith LH. Growth of calcium oxalate crystals: II. Inhibition by natural
urinary crystal growth inhibitors. Invest Urol 1975; 13:36–9
13. Whittaker CF, Miklich MA, Patel RS, Fink JC. Medication Safety Principles and
Practice in CKD. Clin J Am Soc Nephrol 2018;13(11):1738‐1746
14. Robinson MR, Leitao VA, Haleblian GE, et al. Impact of long‐term potassium
citrate therapy on urinary profiles and recurrent stone formation. J Urol 2009;
181:1145–50
15. Sakhaee K, Alpern R, Poindexter J, Pak CY. Citraturic response to oral citric acid
load. J Urol 1992;147(4):975‐6
16. Seltzer MA, Low RK, McDonald M, et al. Dietary manipulation with lemonade to
treat hypocitraturic calcium nephrolithiasis. J Urol 1996; 156:907–9.
17. Odvina CV. Comparative value of orange juice versus lemonade in reducing
stone‐forming risk. Clin J Am Soc Nephrol 2006; 1:1269–74.
18. Patel RM, Jiang P, Asplin J, et al. Coconut water: an unexpected source of
urinary citrate. Biomed Res Int 2018; published online.
19. Eisner BH, Asplin JR, Goldfarb DS, et al. Citrate, malate and alkali content in
commonly consumed diet sodas: implications for nephrolithiasis treatment. J
Urol 2010; 183:2419–23.
20. Pinheiro VB, Baxmann AC, Tiselius HG, et al. The effect of sodium bicarbonate
upon urinary citrate excretion in calcium stone formers. Urol 2013;82(1):33‐7.
21. Sakhaee K, Alpern R, Jacobson HR, et al. Contrasting effects of various
potassium salts on renal citrate excretion. J Clin Endocrinol Metab
1991;72(2):396‐400
22. Phillips R, Hanchanale VS, Myatt A, et al. Citrate salts for preventing and
treating calcium containing kidney stones in adults. Cochrane Database Syst Rev
2015;10:CD010057.

Page 16 of 22

16
23. Frequently asked questions about medical foods, 2nd ed. 2016.
Journal of Endourology
Alkalinizing agents: a review of prescription, over‐the‐counter, and medical food supplements (DOI: 10.1089/end.2019.0292)
This paper has been peer‐reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Downloaded by Thomas Jefferson University from www.liebertpub.com at 08/22/19. For personal use only.

https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulator
yInformation/MedicalFoods/default.html. Accessed February 5, 2019.
24. https://www.bulksupplements.com/potassium‐citrate.html . Accessed February
5, 2019.
25. https://www.nowfoods.com/supplements/potassium‐citrate‐powder.
Accessed February 5, 2019.
26. https://litholyte.com/. Accessed February 5, 2019.
27. https://theralogix.com/products/theralith‐xr‐vitamin‐mineral‐supplement.
Accessed February 5, 2019.
28. Schulsinger D, Kirshenbaum A, Sheynkin Y. 2006. Evaluation of a novel
nutritional supplement to improve urinary magnesium and citrate excretion.
Presented at American Urological Association Annual Conference; May 2006;
Atlanta, GA.
29. https://drinkstonestop.com/?variant=9659715013. Accessed February 5, 2019.
30. https://www.ksptabs.com/. Accessed February 5, 2019.
31. https://kidneycop.com/?gclid=Cj0KCQiAheXiBRD‐
ARIsAODSpWMlQxPgEp8TeQXBHJJOktEHLZhxMSEb1xNJFcVulU‐
MFGsPVu3W6XgaAuAXEALw_wcB. Accessed February 5, 2019.
32. Grases F, Isern B, Sanchis P, et al. Phytate acts as an inhibitor in formation of
renal calculi. Front Biosci 2007; 12:2580‐7.
33. Grases F, Rodriquez A, Costa‐Bauza A. Efficacy of mixtures of magnesium,
citrate and phytate as calcium oxalate crystallization inhibitors in urine. J Urol
2015; 194(3):812‐9.
34. Panigrahi PN, Dey S, Sahoo M, et al. Antiurolithiatic and antioxidant efficacy of
Musa paradisiaca pseudostem on ethylene glycol‐induced nephrolithiasis in rat.
Indian J Pharmacol 2017; 49(1): 77‐83.
35. https://ampurity.com/lithobalance/. Accessed February 5, 2019.

Page 17 of 22

17
36. Asare GA, Bugyei K, Sittie A, et al. Genotoxicity, cytotoxicity and toxicological
Journal of Endourology
Alkalinizing agents: a review of prescription, over‐the‐counter, and medical food supplements (DOI: 10.1089/end.2019.0292)
This paper has been peer‐reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Downloaded by Thomas Jefferson University from www.liebertpub.com at 08/22/19. For personal use only.

evaluation of whole plant extracts of the medicinal plant Phyllanthus niruri
(Phyllanthaceae). Genet Mol Res 2012; 11(1):100‐11.
37. Campos AH, Schor N. Phyllanthus niruri inhibits calcium oxalate endocytosis by
renal tubular cells: its role in urolithiasis. Nephron 1998; 81(4)393‐7.
38. Freitas AM, Schor N, Boim MA. The effect of Phyllanthus niruri on urinary
inhibitors of calcium oxalate crystallization and other factors associated with
renal stone formation. BJU Int 2002; 89(9)829‐34.
39. Pucci ND, Marchini GS, Mazzucchi E, et al. 2018. Effect of phyllanthus niruri on
metabolic parameters of patients with kidney stone: a perspective for disease
prevention. IBJU 2018;44(4):758‐64.
40. Fox S and Duggan M. Health online 2013. Jan 2013.
http://www.pewinternet.org/2013/01/15/health‐online‐2013/. Accessed
February 5, 2019
41. Stephens G. Taking the mystery out of medical foods. Apr 2018.
https://www.nutraceuticalsworld.com/issues/2018‐04/view_columns/taking‐
the‐mystery‐out‐of‐medical‐foods/50213. Accessed February 4, 2019.

Journal of Endourology
Alkalinizing agents: a review of prescription, over‐the‐counter, and medical food supplements (DOI: 10.1089/end.2019.0292)
This paper has been peer‐reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Downloaded by Thomas Jefferson University from www.liebertpub.com at 08/22/19. For personal use only.

Page 18 of 22

Abbreviations
18

American Urological Association
AUA

Food and Drug Administration
FDA

Good manufacturing processes

milli‐equivalent
GMP

Generally Recognized As Safe
GRAS

United States Pharmacopeia
USP

mEq
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Table 1: Comparison of Potassium Citrate and Alternative Supplements*
Name

Main Ingredients

Dosing

Alkali

Price

Approxim

Regulator

Equivale

(US $)

ate Price

y

Per Day**

Informati

nt
Per

on

Serving*

UroCit‐K



K citrate

1‐4

5‐15

$231/

(5, 10, or

tablets

mEq

100

approved

15 mEq

BID

tablets

Prescripti

(10 mEq)

on

tabs)

$15.52

FDA

Required
$388/
100
tablets
(15 mEq)


K citrate

1‐4

5‐15

$138/12

citrate

(5, 10, or

tablets

mEq

0 tabs

generics

(generic)

15 mEq

BID

(15 mEq)

FDA

Potassium

$4.62

approved

tabs)
Varies


Bulk



Several

$186/12

$6.19

Prescripti

K citrate

0

on

packets

packets

Required

99mg K

1

0.92

$11.96/

Supplement

citrate per

serving

mEq

250 g

s

275 mg

daily

$0.40

Made in
FDA
registere
d facility

powder
serving
NOW®
Potassium

Capsule Form:


K+ Citrate

1

0.92

capsule mEq

$11.99/1

$0.07 per

Follows

80

pill

GMP
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Citrate

(99 mg

1‐5x

=0.9 mEq)

daily

capsules

Powder Form:


K+ Citrate

¼
4.15

$12.99/1

mEq) 1.4

on 1‐2x mEq

2 ounces

gm

daily

K+ Citrate

1‐2

(4 mEq)

packets

Mg Citrate

BID

(448 mg= 4 teaspo

Litholyte®




10 mEq

$30/ 60

$1.00

packets

Follows
GMP

(2.5 mEq)


Na
Bicarbonat
e (3.5
mEq)

®

TheraLith X



B6 (7.5mg)

2 tabs

2.12

$60/bott

R



Mg

BID

mEq

le (360

$0.67

Follows
GMP

tabs)

citrate+oxi
de (180 mg
= 1.2 mEq
Mg citrate)


K+ Citrate
(99 mg=
0.9 mEq)

Kidney



C.O.P. ®


Pyridoxine

2 tabs

HCl (5 mg)

daily

$29.95/

$1.00

GRAS

bottle

Follows

Mg Citrate

(60

GMP

(45 mg =

capsules)

0.6 mEq)


5.1 mEq

Citric Acid
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KSPtabs

StoneStop










Phytin

(Inositol)

(200 mg)

Musa

Paradisiac

a (200 mg)

= 0.9 mEq

Mg citrate)

Bicarbonat

e (170 mg

= 2 mEq)

Bicarbonat

e (100 mg

= 1 mEq)


Citrate
2


Magnesiu
packets n
0

m
daily
packets

B6 (7.5
2‐3
2.92
$59.95/8

mg)
tabs
mEq
0 tabs

Mg (64 mg
Daily

Unknow
$29.99/3

B6

No

informatio

n on alkali

equivalent

s or
$1.50

Na

K+

$2.00
Follows

GMP
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by weight

LithoBalanc

*

**



eTM




Vitamin B6
1

(20 mg)
scoop
90

Mg Citrate
(=10
servings

(43 mg =
grams)

0.6 mEq)
2‐3

Potassium
times a

citrate
day

the recommended dosage
4.4 mEq
$49.89 /
$1.11

(410 mg

=3.8 mEq)

The over‐the‐counter supplements provide alkali equivalents that are a fraction of the

recommended dosage.

The Price per day column reflects the suggested dose by the manufacturer only, not

